• Home
  • Microsites
  • Toolbox 206: Helping to Prevent Fractures in Your Patients

Toolbox 206: Helping to Prevent Fractures in Your Patients

In cardiovascular disease we strive to prevent recurrent events (like heart attack or stroke) by intervening right after the event. Fractures are "bone attacks". Let’s have the same intention and attention to our patient’s bones to prevent  “bone attacks”. 

This resource is intended to help achieve that goal. Take a tour to see what these expert physicians are doing in that regard.  You will gain some clinical pearls and tools to help you to help your patients towards the goal of no more fractures.

Click on the resource you would like to learn more about and we hope you can use this information to create your own EMR stamp or flow sheet

Expert Steering Committee
Planning Committee MemberDisclosures
Jonathan D Adachi, MD, FRCPC
The Actavis Chair in Rheumatology for Better Bone Health
Professor, Department of Medicine
Michael G. DeGroote School of Medicine
St. Joseph’s Healthcare
McMaster University
Hamilton, ON
Dr. Adachi received research funding, honoraria, and travel grants from, as well as served on advisory boards and had consulting roles for Acativs, AgNovos, Amgen, Eli Lilly, Merck, and Radius.
Algis V. Jovaisas, MD FRCPC
Rheumatology Adjunct Professor of Medicine
Department of Medicine
Faculty of Medicine
University of Ottawa
Ottawa ON
Dr. Jovaisas received research funding, honoraria, and travel grants from, as well as served on advisory boards and had consulting roles for Alexion, Amgen, Celltrion, Eli Lilly, Gilead, Novartis, Pfizer, Sandoz, and Sanofi-Genzyme.
Jodie M. Reis BHK, MD, FRCPC
Rheumatology Associates of Saskatoon
Physician lead – Saskatoon Fracture Liaison Service (FLS)
Associate Program Director, CBD lead
Rheumatology, University of Saskatchewan
Assistant Professor, University of Saskatchewan
Saskatoon, SK
Dr. Reis received research funding, honoraria, and travel grants from, as well as served on advisory boards and had consulting roles for Amgen, Hospira, Janssen, Lilly, Novartis, Pfizer, Roche, Sanofi, and UCB.
This non-accredited learning activity is financially supported by Amgen Canada and is for healthcare professionals only. This content was developed in concert with the scientific planning committee members and is based on current clinical practice guidelines or expert consensus.

cpdisup